Medico Intercontinental Limited released its FY26 annual report showing a consolidated net loss of Rs 11.09 crore, primarily due to the ongoing scaling phase of its new subsidiary, Calborn Lifescience. While the standalone business remains profitable at Rs 2.18 crore, investors are closely monitoring the Rs 130 crore in proposed related party transactions for the subsidiary and the long-term turnaround strategy for the newly acquired venture.
Medico Intercontinental FY26 Financials and Strategy Update
Standalone Net Profit: Rs 2.18 Crore; Consolidated Net Loss: Rs 11.09 Crore.
Reader Takeaway: Subsidiary investment is weighing on current earnings, but management targets a three-to-four-year turnaround for the new acquisition.
What just happened
Medico Intercontinental Limited (MIL) has filed its annual report for FY26. The company’s consolidated performance has been impacted by the acquisition of a 51% stake in Calborn Lifescience Private Limited. While the parent company reported a standalone profit of Rs 2.18 crore, the consolidated bottom line fell into a loss of Rs 11.09 crore. This divergence marks a significant shift from the previous fiscal year when consolidated profit stood at Rs 4.96 crore.
Why this matters
The financial results highlight the immediate pressure of scaling new manufacturing capabilities. Management has explicitly categorized the losses at Calborn Lifescience as a deliberate investment cost, noting that the subsidiary is currently in a gestation phase expected to last three to four years. Shareholders are now being asked to approve significant related party transactions for FY27, including a Rs 130 crore allocation to Calborn Lifescience, signaling that the company is committing substantial capital to this project.
Related Party Transactions
The company is seeking shareholder approval at its 42nd Annual General Meeting for several transactions:
- Calborn Lifescience Pvt Ltd: Rs 130.00 crore
- Oxford Pharma: Rs 25.00 crore
- Mr. Samir D. Shah: Rs 18.50 crore
- LYF Distributor: Rs 6.00 crore
- Medico LAB: Rs 6.00 crore
What to track next
The 42nd Annual General Meeting will take place on September 30, 2026, via video conferencing. Investors should track progress on the manufacturing scale-up at Calborn Lifescience and evaluate whether the aggressive capital allocation through related party transactions begins to yield positive margin contributions in the coming quarters.